A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland
Titel:
A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland
Auteur:
Panje, C.M. Lupatsch, J.E. Barbier, M. Pardo, E. Lorez, M. Dedes, K.J. Aebersold, D.M. Plasswilm, L. Gautschi, O. Schwenkglenks, M.